Skip to main content

Advertisement

SpringerLink
Log in

Pharmacologic and Pharmacokinetic Assessment of Anti-TGFβ2 Aptamers in Rabbit Plasma and Aqueous Humor

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Purpose

The aim of the study is to determine the bioactivity and effects of PEGylation on the pharmacokinetics in rabbit aqueous humor and plasma of an aptamer directed against TGFβ2.

Methods

Pharmacological activity of anti-TGFβ2 aptamer in rabbit ocular fluid was demonstrated using a mink lung epithelial cell proliferation assay. For pharmacokinetic analyses, concentrations of aptamers in plasma and aqueous humor were determined over time following bilateral subconjunctival administration to Dutch-belted rabbits using a hybridization-based pseudo-enzyme-linked immunosorbent assay (ELISA) assay.

Results

Anti-TGFβ2 aptamer (ARC81) binds to human TGFβ2 with a KD of approximately 5 nM and inhibits the activity of human TGFβ2 in vitro in a cell-based assay with an IC50 of approximately 100 nM. ARC81 blocks endogenously derived TGFβ2 in rabbit aqueous humor in vitro with an IC50 of approximately 200 nM and an IC90 of approximately 1 μM. In vivo in rabbit, ARC81 [no polyethylene glycol (PEG)] entered systemic circulation rapidly (tmax = 1 h in plasma) relative to aptamer conjugates ARC117 (20 kDa PEG) and ARC119 (40 kDa PEG), which showed prolonged residence in the subconjunctival space and aqueous compartment (tmax = 6 and 12 h, respectively, in plasma). Both 20- and 40-kDa aptamer conjugates reached maximal concentrations (Cmax) in aqueous humor of 23–30 nM and remained at or above 1 nM for as long as 12 h.

Conclusions

Pharmacologically active levels of anti-TGFβ2 aptamers can be sustained in the ocular fluid and local tissue environment over a 12-h period after single administration. Daily subconjunctival administration of PEGylated anti-TGFβ2 aptamers should allow further pharmacological evaluation of these agents in a rabbit conjunctival scarring model. Perioperative administration, via subconjunctival injection, may prove to be an effective means to deliver therapeutic quantities of TGFβ2 aptamer conjugates in trabeculectomy procedures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Abbreviations

AUC:

area under the concentration vs. time curve

C max :

highest concentration observed

MLEC:

mink lung epithelial cell

NCA:

noncompartmental analysis

PEG:

polyethylene glycol

SELEX:

systematic evolution of ligands by exponential enrichment

t 1/2 :

terminal half–life

t max :

time at which the highest concentration occurred

V d :

volume of distribution

References

  1. C. Verges J. Cazal C. Lavin (2005) ArticleTitleSurgical strategies in patients with cataract and glaucoma Curr Opin Ophthalmol 16 44–52 Occurrence Handle10.1097/00055735-200502000-00008 Occurrence Handle15650579

    Article  PubMed  Google Scholar 

  2. R. Bindlish G. P. Condon J. D. Schlosser J. D'Antonio K. B. Lauer R. Lehrer (2002) ArticleTitleEfficacy and safety of mitomycin-C in primary trabeculectomy: five-year follow-up Ophthalmology 109 1336–1341 Occurrence Handle10.1016/S0161-6420(02)01069-2 Occurrence Handle12093659

    Article  PubMed  Google Scholar 

  3. D. A. Belyea J. A. Dan R. L. Stamper M. F. Lieberman W. H. Spencer (1997) ArticleTitleLate onset of sequential multifocal bleb leaks after glaucoma filtration surgery with 5-fluorouracil and mitomycin C Am J Ophthalmol 124 40–45 Occurrence Handle1:STN:280:ByiA28rjvFA%3D Occurrence Handle9222231

    CAS  PubMed  Google Scholar 

  4. T. H. Kupin M. S. Juzych D. H. Shin A. K. Khatana M. M. Olivier (1995) ArticleTitleAdjunctive mitomycin C in primary trabeculectomy in phakic eyes Am J Ophthalmol 119 30–39 Occurrence Handle1:STN:280:ByqC38nit1M%3D Occurrence Handle7825687

    CAS  PubMed  Google Scholar 

  5. W. L. Membrey D. P. Poinoosawmy C. Bunce F. W. Fitzke R. A. Hitchings (2000) ArticleTitleComparison of visual field progression in patients with normal pressure glaucoma between eyes with and without visual field loss that threatens fixation Br J Ophthalmol 84 1154–1158 Occurrence Handle1:STN:280:DC%2BD3M%2FgvFGhtA%3D%3D Occurrence Handle11004102

    CAS  PubMed  Google Scholar 

  6. Y. Ochiai H. Ochiai (2002) ArticleTitleHigher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes Jpn J Ophthalmol 46 249–253 Occurrence Handle10.1016/S0021-5155(01)00523-8 Occurrence Handle1:CAS:528:DC%2BD38XksVahsbk%3D Occurrence Handle12063033

    Article  CAS  PubMed  Google Scholar 

  7. M. F. Cordeiro M. B. Reichel J. A. Gay F. D'Esposita R. A. Alexander P. T. Khaw (1999) ArticleTitleTransforming growth factor-beta1, -beta2, and -beta3 in vivo: effects on normal and mitomycin C-modulated conjunctival scarring Investig Ophthalmol Vis Sci 40 1975–1982 Occurrence Handle1:STN:280:DyaK1Mzms1ylsQ%3D%3D

    CAS  Google Scholar 

  8. M. F. Cordeiro J. A. Gay P. T. Khaw (1999) ArticleTitleHuman anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent Investig Ophthalmol Vis Sci 40 2225–2234 Occurrence Handle1:STN:280:DyaK1MvgsVCgtQ%3D%3D

    CAS  Google Scholar 

  9. M. F. Cordeiro A. Mead R. R. Ali R. A. Alexander S. Murray C. Chen C. York-Defalco N. M. Dean G. S. Schultz P. T. Khaw (2003) ArticleTitleNovel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome Gene Ther 10 59–71 Occurrence Handle10.1038/sj.gt.3301865 Occurrence Handle1:CAS:528:DC%2BD3sXivVyksA%3D%3D Occurrence Handle12525838

    Article  CAS  PubMed  Google Scholar 

  10. C. Tuerk L. Gold (1990) ArticleTitleSystematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 505–510 Occurrence Handle1:CAS:528:DyaK3cXlt1OltLY%3D Occurrence Handle2200121

    CAS  PubMed  Google Scholar 

  11. W. A. Pieken D. B. Olsen F. Benseler H. Aurup F. Eckstein (1991) ArticleTitleKinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes Science 253 314–317 Occurrence Handle1:CAS:528:DyaK3MXlslyjtL0%3D Occurrence Handle1857967

    CAS  PubMed  Google Scholar 

  12. J. M. Healy S. D. Lewis M. Kurz R. M. Boomer K. T. Thompson C. Wilson T. G. McCauley (2004) ArticleTitlePharmacokinetics and biodistribution of novel aptamer compositions Pharm Res 21 2234–2246 Occurrence Handle10.1007/s11095-004-7676-4 Occurrence Handle1:CAS:528:DC%2BD2MXjslyjsA%3D%3D Occurrence Handle15648255

    Article  CAS  PubMed  Google Scholar 

  13. S. R. Watson Y. F. Chang D. O'Connell L. Weigand S. Ringquist D. H. Parma (2000) ArticleTitleAnti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo Antisense Nucleic Acid Drug Dev 10 63–75 Occurrence Handle1:CAS:528:DC%2BD3cXivVKlt7s%3D Occurrence Handle10805157

    CAS  PubMed  Google Scholar 

  14. N. Pagratis, M. Lochrie, and L. Gold. High affinity TGFβ nucleic acid ligands and inhibitors, Gilead Sciences, Inc., USA, United States Patent No. 63,466,111, 2002.

  15. P. E. Burmeister S. D. Lewis R. F. Silva J. R. Preiss L. R. Horwitz P. S. Pendergrast T. G. McCauley J. C. Kurz D. M. Epstein C. Wilson A. D. Keefe (2005) ArticleTitleDirect in vitro selection of a 2′-O-methyl aptamer to VEGF Chem Biol 12 25–33 Occurrence Handle10.1016/j.chembiol.2004.10.017 Occurrence Handle1:CAS:528:DC%2BD2MXmtlKnsQ%3D%3D Occurrence Handle15664512

    Article  CAS  PubMed  Google Scholar 

  16. M. Gibaldi D. Perrier (1982) Pharmacokinetics Marcel Dekker Inc. New York

    Google Scholar 

  17. J. C. Jennings S. Mohan T. A. Linkhart R. Widstrom D. J. Baylink (1988) ArticleTitleComparison of the biological actions of TGF beta-1 and TGF beta-2: differential activity in endothelial cells J Cell Physiol 137 167–172 Occurrence Handle10.1002/jcp.1041370120 Occurrence Handle1:CAS:528:DyaL1cXmt1egtL0%3D Occurrence Handle3170656

    Article  CAS  PubMed  Google Scholar 

  18. S. W. Cousins M. M. McCabe D. Danielpour J. W. Streilein (1991) ArticleTitleIdentification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor Investig Ophthalmol Vis Sci 32 2201–2211 Occurrence Handle1:STN:280:By6A3c7pvVU%3D

    CAS  Google Scholar 

  19. A. L. Mead T. T. Wong M. F. Cordeiro I. K. Anderson P. T. Khaw (2003) ArticleTitleEvaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery Investig Ophthalmol Vis Sci 44 3394–3401 Occurrence Handle10.1167/iovs.02-0978

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Sandra Dennis and Dr. John Nash at CTBR-BioResearch Inc. (Montreal, Quebec, Canada) for support of this study and Dr. Judy Healy (Archemix Corp., Cambridge, MA, USA) for help with preparation of the manuscript.

Author information

Authors and Affiliations

  1. Aptamer Pharmacology Group, Archemix Corp., 1 Hampshire Street, Cambridge, Massachusetts, 02139, USA

    Thomas G. McCauley, Jeffrey C. Kurz, Patricia G. Merlino, Scott D. Lewis, Madaline Gilbert, David M. Epstein & H. Nicholas Marsh

Authors
  1. Thomas G. McCauley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey C. Kurz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patricia G. Merlino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott D. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Madaline Gilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David M. Epstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Nicholas Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas G. McCauley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCauley, T.G., Kurz, J.C., Merlino, P.G. et al. Pharmacologic and Pharmacokinetic Assessment of Anti-TGFβ2 Aptamers in Rabbit Plasma and Aqueous Humor. Pharm Res 23, 303–311 (2006). https://doi.org/10.1007/s11095-005-9305-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-005-9305-2

Key Words

Search

Navigation